The neurological complications of Epstein-Barr virus infection include viral meningitis, encephalitis and neuromuscular complications.
The introduction of cerebrospinal fluid polymerase chain reaction for Epstein-Barr virus DNA has improved diagnosis of these conditions and of primary central nervous system lymphoma in acquired immune deficiency syndrome, and has enabled cerebrospinal fluid monitoring of .
Prognosis remains good for most Epstein-Barr virus-related neurological complications;
Background: Complications of Epstein-Barr virus (EBV) infection are diverse and include a number of neurologic manifestations such as meningitis, meningoencephalitis, cerebellitis, cranial neuritis and others. In general encephalitis caused by EBV in pediatric patients has been considered a self-limited illness with few or no sequelae.
Methods: Charts were reviewed from all patients <18 years of age admitted to or discharged from the State University of New York Health Science Center at Syracuse between 1982 and 1992 with a diagnosis of encephalitis or meningoencephalitis.
We provide a comprehensive clinical, radiological and virological analysis of four patients with Epstein–Barr virus (EBV) infection of the nervous system. One patient developed acute myeloradiculitis, one had acute encephalomyeloradiculitis, one had acute meningoencephalomyeloradiculitis and one had a subacute meningomyeloradiculitis.
The ability of EBV to affect multiple parts of the entire neuraxis from meninges and brain to the spinal cord and peripheral nerves was evidenced by combinations of stiff neck and mental status changes,
We report a 22-year-old female who presented with pyrexia, pancytopenia and liver dysfunction. The patient showed mild liver dysfunction with low-grade fever and mild hepatosplenomegaly 6 years previously, and autoimmune hepatitis (AIH) was diagnosed based on the examination of the laboratory data and liver biopsy.
On admission, both markers of Epstein-Barr virus (EBV) and in-situ hybridisation from a liver biopsy specimen indicated chronic active EBV infection (CAEBV).
Idiopathic pulmonary fibrosis (IPF) is characterized by a huge alveolar oxidant burden and a deficiency of glutathione, a major antioxidant, in the pulmonary epithelial lining fluid (ELF). Therefore, a rational therapeutic strategy is to increase lung glutathione to augment the pulmonary antioxidant protective screen.
To evaluate this concept, different doses of N-acetylcysteine (NAC),
Background—Oxygen free radicals have been shown to cause endothelial vasomotor dysfunction. This study examined the effect of reduced glutathione (GSH), an antioxidant, on human coronary circulation.
Methods and Results—Responses of epicardial diameter and blood flow of the left anterior descending coronary artery to intracoronary infusion of acetylcholine (ACh,
OBJECTIVE: To assess the effects of glutathione on pain-free walking distance (PFWD) and hemodynamic parameters in patients with peripheral artery disease.
PATIENTS AND METHODS: Forty patients with Fontaine stage II peripheral artery disease who were seen between September 2000 and March 2001 at the vascular laboratory and ward of the Division of Vascular Medicine and Rehabilitation at Verona University were studied in a double-blind,
Abstract:
Objective: To evaluate the potential of postischemic intravenous infusion of the endogenous antioxidant glutathione (GSH) to protect the liver from reperfusion injury following prolonged warm ischemia.
Background Data: The release of reactive oxygen species (ROS) by activated Kupffer cells (KC) and leukocytes causes reperfusion injury of the liver after warm ischemia.
Abstract Background: Early clinical trials have suggested that glutathione (GSH)offers protection from the toxic effects of cisplatin.
Patients and methods: One hundred fifty-one patients with ovariancancer (stage I–IV) were evaluated in a clinical trial of cisplatin(CDDP) ± glutathione (GSH). The objective was to determine whether GSHwould enhance the feasibility of giving six cycles of CDDP at 100mg/m2 without dose reduction due to toxicity.
Further understanding regarding improvement of macular degeneration with glutathione has occurred since Townsend Letter's June 2001 article about this subject. Thanks to its wide circulation we have received many calls from all over the world, including Switzerland, London and other far away places.
We have seen many more patients, have been able to improve our technique and particularly,
